Rationale for Urine Drug Testing (UDT)

Similar documents
Appropriate Use of UDT to Improve Patient Care

This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics

Urine Drug Testing Methadone 101 Methadone for hospitalists

Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)

Drug Testing to Support Pain Management

Drug Utilization Is On The Rise

The Role of Urine Drug Testing In Chronic Pain Management: 2013 Update

URINE DRUG TESTS IN A PRIVATE CHRONIC PAIN PRACTICE

Session III. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty

Section: Laboratory Last Reviewed Date: December Policy No: 68 Effective Date: April 1, 2016

PtProtect Pain Medication Management Program Monitors Patient Compliance

Urine Drug Testing. Clinical Practice

URINE DRUG TESTING. Effective December 1 st, 2012

Urine Drug Testing in Clinical Practice

Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment

Urine Drug Testing In Pain Management and Opioid Abuse Treatment Corporate Medical Policy

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians

What Americans Believe. Grant Beardsley, MS, MT(ASCP) 10/12/2015. Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse

Southlake Psychiatry. Suboxone Contract

Implementing Prescribing Guidelines in the Emergency Department. April 16, 2013

Urine Drug Testing in Pain Medicine

Name of Policy: Urine Drug Testing in Pain Management

BEST PRACTICES IN DRUG TESTING OF HEALTHCARE PROFESSIONALS

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

Visit to hear more of my story or call 211 for help and treatment options

Opioid Treatment Guidelines. Denis G. Patterson, DO University of Nevada, Reno 7/15/2015

Arkansas Emergency Department Opioid Prescribing Guidelines

Practice Protocol. Buprenorphine Guidance Protocol

Drug Abuse & Alcoholism

Central Government Laboratory Department of Health and Environment

MOSAIC DES MOINES Alcohol/Drug Free Workplace Policy

Drug Testing & Office Based Detoxification

Appropriate utilization of drug tests for pain management patients

A Review of the Impacts of Opiate Use in Ontario: Summary Report

Table of Contents. I. Introduction II. Summary A. Total Drug Intoxication Deaths B. Opioid-Related Deaths... 9

Clinic Reference Guide


Triage, Assessment & Treatment Methadone 101/Hospitalist Workshop

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15

Opioids for Pain Treatment. Opioids for Chronic Pain and Addiction Treatment. Outline for Today. Opioids for pain treatment

We re glad you are here! Agenda for the Day Breaks Lunch Q&A and note cards Phones

Opiates Agreements and Drug testing in Pain Management

Collection Instructions for ARUP Drug Screen Kit #49204

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

A Report on Marijuana and Prescription Drugs

Blueprint for Prescriber Continuing Education Program

Considerations when Using Controlled Substances to Treat Chronic Pain

8/1/2014. Who We Are. BHG s Medical Mission. BHG Company Overview

MEDICAL ASSISTANCE BULLETIN

Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas

MEDICAL ASSISTANCE BULLETIN

The Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Prescription drug abuse trends. Minnesota s Prescription Monitoring Program. Minnesota Rural Health Conference June 25, 2013 Duluth

Pain and problem drug use

OPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to

Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain

Clinical Drug Testing in Primary Care

Jane Maxwell, UT Addiction Research Institute, Prescription Pain Medications and Heroin: A Changing Picture

Massachusetts Substance Abuse Policy and Practices. Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District

LC-MS for Pain Management Support. Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories

Discontinuation: Involuntary Discharge

The Benefits of a Creating a Healthy Work Environment

Drug- and Alcohol-Related Intoxication Deaths in Maryland, 2014

LC-MS for Pain Management Support

HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES

OBJECTIVES. ! Understand the rising epidemic of prescription drug abuse in Wyoming. ! Know how to access and use reports from the WORx program

Policy for the issue of permits to prescribe Schedule 8 poisons

Bermuda Hospitals Board Drug Screening Programme

DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015

Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain

Opioid Addiction & Methadone Maintenance Treatment. What is Methadone? What is an Opioid?

Alcohol & Chemical Dependence. Chisoo Choi, M.D. Internal Medicine Consultant Brookhaven Hospital Tulsa, Oklahoma

TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION

Knowing the Facts About Medication Adherence Among Those with Serious Mental Illness

Toxicology CPT Code Changes for 2016

Testimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013

PARTNERSHIP HEALTHPLAN RECOMMENDATIONS For Safe Use of Opioid Medications

American Society of Addiction Medicine

SAFE PAIN MEDICATION PRESCRIBING GUIDELINES

Laboratory Insights into the New Drug Epidemic

Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions

Pain, Addiction & Methadone

Palmer MacKie, MD MS Director, Integrative Pain Program, Eskenazi Department of Medicine, IUSOM

Strategic Plan for Alcohol and Drug Abuse

Federal and State Laws Relating to Prescribing of Controlled Substances

Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications

Transcription:

Rationale for Urine Drug Testing (UDT) Help to identify drug misuse/addiction Prior to starting opioid treatment Assist in assessing adherence during opioid therapy As requirement of therapy w/ an opioid Support decision to refer UDT frequency is based on clinical judgment Depending on patient s display of aberrant behavior and whether it is sufficient to document adherence to treatment plan Check state regulations for requirements 1

Main Types of UDT Methods Initial testing w/ IA drug panels: Classify substance as present or absent according to cutoff Many do not identify individual drugs within a class Subject to cross-reactivity Either lab based or at POC Identify specific drugs &/or metabolites w/ sophisticated lab-based testing; e.g., GC/MS or LC/MS* Specifically confirm the presence of a given drug e.g., morphine is the opiate causing a positive IA* Identify drugs not included in IA tests When results are contested * GC/MS=gas chromatography/ mass spectrometry IA=immunoassay LC/MS=liquid chromatography/ mass spectrometry 2

Detecting Opioids by UDT Most common opiate IA drug panels GC/MS or LC/MS will identify specific opioids Detect opiates morphine & codeine, but doesn t distinguish Confirm presence of a drug causing a positive IA Do not reliably detect semisynthetic opioids Do not detect synthetic opioids (e.g., methadone, fentanyl) Specific IA panels can be ordered for some Only a specifically directed IA panel will detect synthetics Identify opioids not included in IA drug panels, including semisynthetic & synthetic opioids Lab can identify specific opioids at physician request 3

Interpretation of UDT Results Positive result Demonstrates recent use Most drugs in urine have detection times of 1-3 d Chronic use of lipidsoluble drugs: test positive for 1 wk Does not diagnose Drug addiction, physical dependence, or impairment Does not provide enough information to determine Exposure time, dose, or frequency of use Negative result Does not diagnose diversion More complex than presence or absence of a drug in urine May be due to maladaptive drugtaking behavior Bingeing, running out early Other factors: e.g., cessation of insurance, financial difficulties 4

Interpretation of UDT Results, cont d Be aware Testing technologies & methodologies evolve Differences exist between IA test menu panels vary Cross-reactivity patterns Maintain list of all patient s prescribed & OTC drugs Assist to identify false-positive result Cutoff levels Time taken to eliminate drugs Document time of last use & quantity of drug(s) taken Opioid metabolism may explain presence of apparently unprescribed drugs 5

Examples of Metabolism of Opioids Codeine Morphine 6-MAM* Heroin t ½ =25-30 min t ½ =3-5 min Hydrocodone Hydromorphone Oxycodone Oxymorphone Not comprehensive pathways, but may explain presence of apparently unprescribed drugs *6-MAM=6-monoacetylmorphine 6

Interpretation of UDT Results Use UDT results in conjunction w/ other clinical information Investigate unexpected results Discuss w/ the lab Schedule appointment w/ patient to discuss unexpected/abnormal results Chart results, interpretation, & action Do not ignore the unexpected positive result May necessitate closer monitoring &/or referral to a specialist Gourlay DL, et al. Urine Drug Testing in Clinical Practice. The Art & Science of Patient Care. Ed 4. 2010. 7

Be Ready to Refer Be familiar w/ referral sources for abuse or addiction that may arise from use of ER/LA opioids SAMHSA substance abuse treatment facility locator http://findtreatment.samhsa.gov/treatme ntlocator/faces/quicksearch.jspx SAMHSA mental health treatment facility locator http://findtreatment.samhsa.gov/mhtreat mentlocator/faces/quicksearch.jspx 8